Opsy Holding

Opsy Holding FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Opsy Holding (OPSYH.SL) as of Oct 28, 2026 is 55.70 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 10.71 % — a change of 420.06% (higher).

FCF Conversion

55.70 %

YoY

420.06%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Opsy Holding is 2025 55.70 % . FCF Conversion Rate (FCF/EBITDA) of Opsy Holding was 2024 10.71 % . It decreases by 420.06% higher compared to the previous year.

The Opsy Holding FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
74.49 SEK
Jan 1, 2019
116.01 SEK
Jan 1, 2020
104.94 SEK
Jan 1, 2021
86.95 SEK
Jan 1, 2022
117.61 SEK
Jan 1, 2023
94.67 SEK
Jan 1, 2024
10.71 SEK
Jan 1, 2025
55.70 SEK
The Opsy Holding FCF Conversion history
YEARFCF ConversionYoY
55.70 %+420.06%
10.71 %-88.69%
94.67 %-19.51%
117.61 %+35.26%
86.95 %-17.14%
104.94 %-9.54%
116.01 %+55.74%
74.49 %-26.77%
101.71 %+4.98%
96.89 %-5.95%
103.01 %-55.02%
229.02 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Opsy Holding Stock analysis

What does Opsy Holding do? Opsy Holding AB develops a software platform for insurance companies and medical advisors, focusing on anti-metastatic therapies related to the Wnt-5a protein. The company's products target the metastatic process through specific small molecules that interact with Wnt-5a mechanisms. Insurance companies and medical advisors purchase the platform to integrate advanced therapeutic insights into their services. The company's primary market segment consists of healthcare technology providers seeking innovative solutions for metastasis research. Opsy Holding AB's software platform is designed to support medical advisors and insurance firms in evaluating small molecules that specifically interact with the Wnt-5a protein's role in metastasis. The company's focus on Wnt-5a mechanisms positions its products for specialized healthcare applications. Insurance companies use the platform to enhance their risk assessment models with advanced therapeutic data. The company's business model centers on providing a technology platform that bridges medical research and insurance applications. By targeting the Wnt-5a protein's role in metastasis, Opsy Holding AB offers a niche solution for healthcare technology providers. The platform's value lies in its ability to connect specific small molecule evaluations with practical applications in insurance and medical advisory services. Opsy Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opsy Holding stock

FCF Conversion Rate (FCF/EBITDA) of Opsy Holding is 55.70 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Opsy Holding changed from 10.71 % to 55.70 %, representing a 420.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Opsy Holding since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Opsy Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Opsy Holding

All Key Metrics — Opsy Holding